GDERF
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes ACTINICA, Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Sool… Read more
GDERF (GDERF) - Net Assets
Latest net assets as of June 2025: $7.73 Billion USD
Based on the latest financial reports, GDERF (GDERF) has net assets worth $7.73 Billion USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.88 Billion) and total liabilities ($5.15 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.73 Billion |
| % of Total Assets | 60.03% |
| Annual Growth Rate | 44.98% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
GDERF - Net Assets Trend (2023–2024)
This chart illustrates how GDERF's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GDERF (2023–2024)
The table below shows the annual net assets of GDERF from 2023 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $7.79 Billion | +45.09% |
| 2023-12-31 | $5.37 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to GDERF's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 657700000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $5.68 Billion | 72.86% |
| Other Components | $2.11 Billion | 27.14% |
| Total Equity | $7.79 Billion | 100.00% |
GDERF Competitors by Market Cap
The table below lists competitors of GDERF ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
W P Carey Inc
NYSE:WPC
|
$15.57 Billion |
|
Kratos Defense & Security Solutions Inc.
LSE:0JS0
|
$15.58 Billion |
|
Singapore Airlines Ltd
PINK:SINGY
|
$15.61 Billion |
|
Public Bank Bhd
KLSE:1295
|
$15.62 Billion |
|
Reliance Steel & Aluminum Co
NYSE:RS
|
$15.56 Billion |
|
Entegris Inc
NASDAQ:ENTG
|
$15.47 Billion |
|
Rentokil Initial PLC
NYSE:RTO
|
$15.41 Billion |
|
Arm Holdings plc
F:O9T
|
$15.39 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GDERF's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,369,000,000 to 7,790,000,000, a change of 2,421,000,000 (45.1%).
- Net income of 231,000,000 contributed positively to equity growth.
- Share repurchases of 15,000,000 reduced equity.
- New share issuances of 2,166,000,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $231.00 Million | +2.97% |
| Share Repurchases | $15.00 Million | -0.19% |
| Share Issuances | $2.17 Billion | +27.8% |
| Other Changes | $39.00 Million | +0.5% |
| Total Change | $- | 45.09% |
Book Value vs Market Value Analysis
This analysis compares GDERF's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.29x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 4.78x to 3.29x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2023-12-31 | $22.60 | $108.10 | x |
| 2024-12-31 | $32.81 | $108.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GDERF utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.20%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.62x
- Recent ROE (2.97%) is above the historical average (0.95%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | -1.06% | -1.38% | 0.33x | 2.32x | $-593.90 Million |
| 2024 | 2.97% | 5.20% | 0.35x | 1.62x | $-548.00 Million |
Industry Comparison
This section compares GDERF's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GDERF (GDERF) | $7.73 Billion | -1.06% | 0.67x | $15.56 Billion |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |